The identification of ERBB2 mutations in 14% of patients, 2.1% of daughters, and 1.2% of sisters (Table 3) suggests a genetic basis for increased susceptibility in first-degree relatives, particularly in populations with high familial breast cancer prevalence, such as in Egypt. Here, ERBB2 is linked to breast cancer.